Public Employees Retirement System of Ohio Buys New Shares in Becton, Dickinson and Company $BDX

Posted by Geri Gentry on Aug 31st, 2026

Public Employees Retirement System of Ohio bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 98,188 shares of the medical instruments supplier’s stock, valued at approximately $14,859,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $25,000. SHP Wealth Management bought a new stake in Becton, Dickinson and Company in the 4th quarter valued at $26,000. Prosperity Bancshares Inc acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at $29,000. Meeder Asset Management Inc. boosted its position in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the period. Finally, Tucker Asset Management LLC acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $34,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Up 0.1%

Shares of Becton, Dickinson and Company stock opened at $189.71 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The firm has a 50-day moving average of $166.14 and a 200-day moving average of $160.20. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $193.07. The stock has a market cap of $52.27 billion, a PE ratio of 57.14, a PEG ratio of 13.36 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Royal Bank Of Canada increased their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Bank of America reduced their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Finally, Piper Sandler upped their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $185.67.

View Our Latest Stock Report on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.